INS and type 2 diabetes mellitus: Sulfonylureas are ubiquitously employed as antidiabetic drugs for type 2 diabetes mellitus (T2DM) with characteristics of the deficiency of insulin secretion and/or insulin resistance (IR), a metabolic illness afflicting millions of people worldwide (Rorsman and Ashcroft, 2018).